Pro Medicus (ASX:PME) Launches 10% Share Buyback: What It Signals for ASX Healthcare Investors

When a company's share price falls nearly 46% yet management turns around and commits to buying back 10% of its own stock, that is a signal worth examining closely.

That is exactly what happened today. Pro Medicus (ASX: PME), one of Australia's most closely watched ASX healthcare stocks, announced an on-market share buyback of up to 10.4 million shares, representing around 10% of its issued capital. The programme runs from 1 April 2026 to 31 March 2027 and will be executed through Goldman Sachs.

For investors, the timing raises an important question: what does management see that the broader market is currently missing?

What Is a Share Buyback and Why Does It Matter?

A share buyback is simply when a company uses its own cash to purchase shares from the open market. As more shares are retired, each remaining share represents a slightly larger stake in the business, which can lift earnings per share over time even if underlying profits stay flat.

More importantly, buybacks are one of the clearest signals of management confidence. Boards do not commit hundreds of millions of dollars to repurchasing their own stock unless they genuinely believe the current price undervalues the business.

Pro Medicus does not require shareholder approval for this programme. Under Australian corporate law, companies can repurchase up to 10% of their shares within a 12-month period without a shareholder vote, a threshold known as the 10/12 limit. The PME buyback sits precisely within that boundary, meaning the board is moving quickly and decisively without needing to call a meeting or seek a resolution.

‍

Why ASX Healthcare Stocks Have Struggled in 2026

To put the PME buyback in context, it helps to understand why the broader ASX healthcare technology sector has been under pressure.

Two forces have weighed heavily. First, rising interest rates have made high-growth, high-valuation stocks less attractive to investors. When rates climb, the value placed on future earnings falls, and growth companies tend to get hit hardest.

Second, the rapid rise of artificial intelligence sparked anxiety across the software sector. Investors began questioning whether AI tools could eventually disrupt established software platforms, including in healthcare.

The result has been a broad selloff of quality ASX healthcare and technology stocks, even for companies whose revenues and profits continued to grow strongly. Pro Medicus is a clear example of this disconnect.

Pro Medicus: Strong Fundamentals, Discounted Price

Pro Medicus develops medical imaging software used by hospitals, primarily across the United States. Its flagship product, Visage 7, allows radiologists to view and analyse complex medical scans rapidly from any device, anywhere in the world.

The company's H1 FY2026 results, released in February 2026, showed revenue of A$124.8 million, up 28.4% year-on-year, with underlying profit after tax rising 29.7% to A$90.7 million. Yet the stock fell approximately 24% on results day as investors reacted to concerns about slowing growth momentum and AI disruption risk.

Today's buyback, executed at scale through Goldman Sachs, is the board's clearest response to that selloff. With the stock down roughly 46% year to date in 2026, management appears to believe current prices represent a meaningful discount to the true value of the business.

What Investors Should Watch Next

The buyback does not erase the risks. Key considerations for investors include:

• Valuation: Even after its sharp selloff, PME still trades at a premium to most ASX peers. Investors need to weigh that premium against the quality and growth track record of the business.
  
  
• AI impact: The market's fear that AI will disrupt Visage is largely a sentiment issue rather than a structural one. Pro Medicus has built native AI directly into Visage 7, supporting automated workflow prioritisation, AI-powered reporting, and third-party algorithm integration. The CEO publicly dismissed disruption concerns in February 2026, positioning AI as a growth driver rather than a threat. Whether that execution delivers as promised remains the key debate for investors.
  
  
• Currency risk: With 90% of revenue generated from North American operations, movements in the AUD/USD exchange rate can significantly affect reported Australian earnings.
  
  
• Next catalyst: Full-year FY2026 results are due 19 August 2026, the most important near-term test of whether revenue growth has re-accelerated.

Key Takeaways

• Pro Medicus has launched a 10% on-market buyback today, one of the strongest management confidence signals available to a listed company.
• Underlying business fundamentals remain strong, with 28.4% revenue growth in H1 FY2026 despite the sharp share price decline.
• The gap between price and fundamentals is the core debate for investors in ASX healthcare stocks heading into the August full-year results.

‍

‍

Ready to explore which ASX healthcare and growth stocks make our analysts' shortlist? Download ASR's free Top-3 Stocks and Market Outlook Report for our latest sector opportunities and stock picks.

‍